Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$0.00$0.00— vs Q1 2020 Net Income-$6.06M-$6.06MN/M vs Q1 2020 EPS Diluted-$0.12-$0.12N/M vs Q1 2020 Operating Income-$6,031,463N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,431,353N/M ended Mar 31, 2021 · filed May 14, 2021 · 44 d after period end